Growth-centric healthcare executives bring 40 years of executive leadership experience in multiple industrial sectors
new york, September 25th, 2025 /PRNewswire/ -Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid” or “Company”), PAVMED Inc. (NASDAQ: PAVM), Cancer Prevention Medical Diagnostics Company and its subsidiary (“Company”) today announced the appointment of skilled healthcare executives. John R. Palumbo Effective for board meetings September 22, 2025.
“John is a very skilled executive and his 40-year healthcare leadership experience spans early stage ventures, growth stage companies and Fortune 100 companies,” he said. Richan AcklogChairman and CEO of MD, Lucid. “His vast experience and deep expertise involves guiding early stage companies through commercial growth.
“We are honored to be part of the Meid Committee at such a critical stage of development,” Palumbo said. “Lucid addresses the huge unmet need in cancer prevention with ESOGUARD. We look forward to working closely with our leadership team, Dr. Aklog and fellow directors, to guide our company's strategy and position it for long-term success.”
Palumbo is a senior medical executive with a four-year career spanning early stage ventures, growth companies and Fortune 100 companies. He launched two companies through IPOs, scaled up startups and led major transformation initiatives in large, complex organizations. Most recently, he served as executive chairman of ValueHealth, a value-based surgical platform, and led the company through recapitalization in 2018 and strategic investments in 2022.
Previously, he served as a senior executive role at Amerisourcebergen Corporation (NYSE: ABC, now Cencora, Inc.), leading the provider business unit and its consulting and technical departments. During his tenure, the group expanded to a multi-billion dollar platform serving health systems across the country.
Previously, Palumbo was also a member of Allscripts Healthcare Solutions, Inc. He is Chief Operating Officer of (NASDAQ: MDRX) and oversaw the company's transformation from the physician dispensing business to one of the industry's first electronic medical record platforms. Before that, he was I-Trax, Inc. He served as president of (now part of Premise Health Holding Corp.) and built it into a national leader in on-site primary care, pharmacy and population health services for Fortune 500 employers.
He began his career in the Shared Health System (SMS), where he led National Health Services and Outsourcing Services. SMS was later acquired in 2000 by Siemens Healthineers AG (FWB:SHL).
For the past 15 years, Palumbo has served as chairman, director and senior advisor for healthcare technology, services and medical device companies supported by institutional and strategic investors. He currently serves on the committees of PM Pediatrics, IVWatch and Qless, and serves as a chair on the advisory board of Brado, an AI-led engagement platform that serves Health Systems.
About the diagnosis of ID
Lucid Diagnostics Inc. is a commercial stage, Cancer Prevention Medical Diagnostics Company and a subsidiary of Pavmed Inc. (NASDAQ: PAVM). Lucid focuses on millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, at risk of developing pre-esophageal pre-cancerous and cancer. Lucid's ESOGUARD® Esophageal DNA Test, performed on samples collected in short, non-invasive office procedures using the ESOCHECK® Esophageal Cell Collector, represents the first and only commercially available tool designed to prevent spreading and cancer death, representing the early detection of pre-esophageal pregnant women in risky patients.
For more information about Lucid, please visit www.luciddx.com. For more information about our parent company, Pavmed, please visit www.pavmed.com.
Forward-looking statements
This press release contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements based on our current beliefs and expectations in the management of Lucid are subject to risks and uncertainties, and actual results may differ from forward-looking statements. The risks and uncertainties that could cause such differences include, among other things, volatility in the price of Lucid's common stock. General economic and market conditions; uncertainty inherent in research and development, including the costs and time required to advance Lucid products to regulatory submissions. Whether regulators are satisfied with the design and results of Lucid's clinical and preclinical research. If and when is Lucid's products cleared by regulators? The market acceptance of Lucid's products was once dismissed and commercialized. Lucid's ability to raise additional funds as needed. Other competitive developments. Additionally, Lucid continues to monitor the Covid-19 pandemic and the impact of the pandemic on Lucid's business. These factors are difficult or impossible to predict accurately, many of which are beyond Lucid's control. Additionally, new risks and uncertainties can sometimes arise, making them difficult to predict. See Part I, Item 1A, Risk Factors for a further list and explanation of these and other important risks and uncertainties that may affect future operations of Lucid. Lucid disclaims any intention or obligation to publicly update or revise forward-looking statements to reflect changes in expectations, events, conditions or circumstances that may be based on those expectations or that actual results may differ from those contained in forward-looking statements.
SourceLucid Diagnostics
